全文获取类型
收费全文 | 210412篇 |
免费 | 15164篇 |
国内免费 | 751篇 |
专业分类
耳鼻咽喉 | 2284篇 |
儿科学 | 5483篇 |
妇产科学 | 4305篇 |
基础医学 | 27107篇 |
口腔科学 | 4514篇 |
临床医学 | 20001篇 |
内科学 | 44914篇 |
皮肤病学 | 2754篇 |
神经病学 | 20303篇 |
特种医学 | 6952篇 |
外国民族医学 | 13篇 |
外科学 | 32926篇 |
综合类 | 3413篇 |
现状与发展 | 2篇 |
一般理论 | 291篇 |
预防医学 | 19074篇 |
眼科学 | 4373篇 |
药学 | 14392篇 |
1篇 | |
中国医学 | 374篇 |
肿瘤学 | 12851篇 |
出版年
2023年 | 844篇 |
2022年 | 1406篇 |
2021年 | 3442篇 |
2020年 | 2105篇 |
2019年 | 3390篇 |
2018年 | 3967篇 |
2017年 | 3214篇 |
2016年 | 3411篇 |
2015年 | 4069篇 |
2014年 | 6096篇 |
2013年 | 8824篇 |
2012年 | 13127篇 |
2011年 | 14325篇 |
2010年 | 8101篇 |
2009年 | 7308篇 |
2008年 | 13590篇 |
2007年 | 14428篇 |
2006年 | 13921篇 |
2005年 | 14398篇 |
2004年 | 13807篇 |
2003年 | 12903篇 |
2002年 | 12438篇 |
2001年 | 1880篇 |
2000年 | 1468篇 |
1999年 | 2049篇 |
1998年 | 2830篇 |
1997年 | 2438篇 |
1996年 | 2206篇 |
1995年 | 1953篇 |
1994年 | 1755篇 |
1993年 | 1656篇 |
1992年 | 1210篇 |
1991年 | 1150篇 |
1990年 | 1055篇 |
1989年 | 954篇 |
1988年 | 1012篇 |
1987年 | 1019篇 |
1986年 | 1002篇 |
1985年 | 1086篇 |
1984年 | 1479篇 |
1983年 | 1461篇 |
1982年 | 1815篇 |
1981年 | 1639篇 |
1980年 | 1555篇 |
1979年 | 815篇 |
1978年 | 958篇 |
1977年 | 933篇 |
1976年 | 831篇 |
1975年 | 684篇 |
1974年 | 667篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
Sixty-three mallards were fed one of ten poly(methyl methacrylate) based synthetic grit formulations containing varying concentrations of a proposed wildlife contraceptive (nicarbazin), plasticizer (acetyl tributylcitrate) and/or cross-linking agent (1,4-butanediol diacrylate). Release characteristics of the contraceptive agent were monitored for the purpose of developing a contraceptive formulation for control of pest waterfowl in urban settings. The addition of plasticizer increased the erosion rate (t(1/2)=0.97-2.85 days), cross-linking the polymer matrix slightly decreased the erosion rate (t(1/2)=4.45-5.05 days) and increasing the concentration of the contraceptive agent increased the erosion rate (t(1/2)=3.3 and 9.9 days at 60% and 7.5% active ingredient, respectively). The larger and smaller grit pieces had longer half lives at 11.0 and 11.6 days, respectively while the mid sized grit had a half life of 4.95 days. Control grit had a half life of 12.7 days based on weight loss. Analysis of blood and feces for monitoring release from the grit and approximate indirect plasma levels of the active ingredient proved feasible. 相似文献
72.
73.
74.
Anorectal function in the solitary rectal ulcer syndrome 总被引:8,自引:6,他引:2
Nigel R. Womack F.R.C.S. Professor Norman S. Williams M.S. John H. Holmfield Mist John F. Morrison Ph.d. 《Diseases of the colon and rectum》1987,30(5):319-323
The anorectal function of nine patients with solitary rectal ulcer syndrome (SRUS) (5 F: 4 M, median age, 27 (range, 19–41
years) and nine control subjects (5 F: 4 M, median age, 47 (35–66)P<0.01) has been investigated by a new technique that radiologically visualizes the anorectum during voiding of a semisolid
contrast medium, while simultaneously measuring intrarectal pressure and anal sphincter EMG activity. A degree of rectal prolapse
was demonstrated in eight of the SRUS patients; six of these lesions were clinically occult. Abnormal failure of the anal
sphincter to relax on voiding was present in seven of the SRUS patients. These abnormalities resulted in the SRUS patients
requiring a greater increase in intrarectal pressure (median, 100 cm water) to void than the control subjects (median, 65
cm water,P<0.01). This combination of high intrarectal pressure and rectal prolapse during straining seems to be the cause of SRUS
This work was supported by a grant from the Medical Research Council. 相似文献
75.
76.
77.
78.
Peter D. Le Roux David S. Jardine Paul M. Kanev John D. Loeser 《Child's nervous system》1991,7(1):34-39
We reviewed the results of all pediatric patients undergoing intracranial pressure (ICP) monitoring in a 2-year period at our institution. The outcome of patients suffering hypoxia or ischemic injuries (HII) is compared to those suffering non-hypoxic or non-ischemic injuries (NHII). Thirty-four patients had ICP monitors placed during the study period. Inconplete patient information led to the exclusion of 5 patients. An additional 5 patients were excluded because no measures to control ICP were taken after the monitor was placed. Twenty-four patients required treatment for raised ICP (hyperventilation, 24; mannitol, 19; barbiturate coma, 6). Admission Glasgow Coma Score in patients suffering HII (median score 5) and NHII (median score 6) were not significantly different (Mann-Whitney U Test). Only 2 of 8 patients with HII were near-drowning vietims. The remaining 6 had HII from other causes (5 survivors of various forms of asphyxia and 1 of cardiac arrest). All 8 patients had poor outcomes (1 severely disabled; 7 died). The 16 patients with NHII had a variety of diagnoses (6 trauma, 5 encephalitis, 4 bacterial meningitis, 1 diabetic ketoacidosis). Among these, 6 had good outcomes and 10 poor outcomes (2 severely disabled, 2 vegetative, and 6 died). The difference in outcome between patients with NHII and HII is significant at P=0.059 (Fischer Exact test). Patients with NHII may benefit from ICP monitoring. Patients with HII from near-drowning and other causes did not appear to benefit from ICP monitoring and interventions directed at controlling ICP. 相似文献
79.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献
80.